Mantle cell lymphoma: An update on management Journal Article


Author: Zelenetz, A. D.
Article Title: Mantle cell lymphoma: An update on management
Abstract: Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate does not reach a plateau. Radioimmunotherapy has substantial single-agent activity and when combined with chemotherapy may provide a platform onto which rituximab or autologous stem cell transplantation can be added. Targeted therapies are also showing promise and may have a role in maintenance and/or initial therapy. © 2006 Oxford University Press.
Keywords: cancer survival; treatment failure; acute granulocytic leukemia; prednisone; clinical trial; doxorubicin; cancer growth; conference paper; alpha interferon; combined modality therapy; cytarabine; methotrexate; rituximab; drug megadose; antineoplastic agent; apoptosis; bortezomib; mantle cell lymphoma; etoposide; blood toxicity; antineoplastic combined chemotherapy protocols; maintenance therapy; antifungal agent; cyclophosphamide; dexamethasone; melphalan; vincristine; autologous stem cell transplantation; stem cell transplantation; antineoplastic activity; carmustine; temsirolimus; cancer regression; antiinfective agent; folinic acid; cancer relapse; flavopiridol; mesna; radioimmunotherapy; tositumomab i 131; lymphoma, mantle-cell; targeted therapies; myelodysplasia
Journal Title: Annals of Oncology
Volume: 17
Issue: Suppl.4
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2006-05-01
Start Page: iv12
End Page: iv14
Language: English
DOI: 10.1093/annonc/mdj992
PUBMED: 16702178
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 16" - "Export Date: 4 June 2012" - "CODEN: ANONE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    767 Zelenetz